Article

A Phase I, Open-Label Study of Siltuximab, an Anti-IL-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease.

Solid Tumor Therapeutics, University of California San Diego, Moores Cancer Center.
Clinical Cancer Research (Impact Factor: 8.19). 05/2013; 19(13). DOI: 10.1158/1078-0432.CCR-12-3349
Source: PubMed

ABSTRACT PURPOSE: To evaluate the safety and pharmacokinetics of siltuximab, an anti-interleukin-6 chimeric mAb in patients with B-cell non-Hodgkin's lymphoma (NHL), multiple myeloma (MM), or Castleman's disease (CD). EXPERIMENTAL DESIGN: In an open-label, dose-finding, seven-cohort, phase I study, patients with NHL, MM, or symptomatic CD received siltuximab 3, 6, 9, or 12 mg/kg qw, q2w, or q3w. Response was assessed in all disease types. Clinical benefit response (CBR: composite of hemoglobin, fatigue, anorexia, fever/night sweats, weight, largest lymph node size) was also evaluated in CD. RESULTS: Sixty-seven patients received a median of 16 siltuximab doses for a median of 8.5 (maximum 60.5) months; 29 were treated ≥1 year. There was no DLT, antibodies to siltuximab, or apparent dose-toxicity relationship. The most frequently reported possibly drug-related AEs were thrombocytopenia (25%), hypertriglyceridemia (19%), neutropenia (19%), leukopenia (18%), hypercholesterolemia (15%), and anemia (10%). None of these events led to dose delay/discontinuation except for neutropenia and thrombocytopenia (n=1 each). No treatment-related deaths occurred. CRP suppression was most pronounced at 12-mg/kg q3w. Mean terminal-phase half-life ranged 17.73-20.64 days. 32/37 (86%) CD patients improved in ≥1 CBR component; 12/36 evaluable CD patients had radiologic response (CR, n=1; PR, n=11), including 8/19 treated with 12 mg/kg; 2/14 (14%) evaluable NHL patients had PR; 2/13 (15%) MM patients had CR. CONCLUSIONS: No dose-related or cumulative toxicity was apparent across all disease indications. A dose of 12-mg/kg-q3w was recommended based on the high response rates in CD and the sustained CRP suppression. Randomized studies are ongoing in CD and MM.

2 Followers
 · 
177 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Multiple myeloma is a life-threatening haematological malignancy for which standard therapy is inadequate. Autologous stem cell transplantation results in effective cytoreduction, but patients subsequently relapse from sites of chemotherapy-resistant disease. Allogeneic transplantation may result in durable responses due to anti-tumour immunity mediated by donor lymphocytes. However, morbidity and mortality related to graft-vs-host disease remains a challenge. A promising area of investigation is the development of immunotherapeutic approaches that target and eliminate myeloma cells more selectively. A variety of tumour-associated antigens have been identified in myeloma cells that may be targeted selectively by host immunity. Vaccination strategies targeting single antigens and whole-cell approaches, which have the advantage of presenting patient-specific and potentially unidentified antigens to immune effector cells, have shown promise in clinical studies. In addition, the use of monoclonal antibodies has been evaluated in preclinical and clinical studies. Effector cell dysfunction and the increased number of regulatory T cells in patients with malignancy may limit the efficacy of immunotherapeutic approaches. Strategies to improve upon immunotherapy for multiple myeloma involve the depletion of T regulatory cells, combining active and passive immunotherapy, the use of cytokine adjuvants, and using immunotherapy in conjunction with autologous and allogeneic transplantation.
    Bailli&egrave re s Best Practice and Research in Clinical Haematology 10/2008; 21(3):559-77. DOI:10.1016/j.beha.2008.07.007 · 2.55 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Interleukin-6 (IL-6) is a pleiotropic cytokine with significant functions in the regulation of the immune system. As a potent pro-inflammatory cytokine, IL-6 plays a pivotal role in host defense against pathogens and acute stress. However, increased or deregulated expression of IL-6 significantly contributes to the pathogenesis of various human diseases. Numerous preclinical and clinical studies have revealed the pathological roles of the IL-6 pathway in inflammation, autoimmunity, and cancer. Based on the rich body of studies on biological activities of IL-6 and its pathological roles, therapeutic strategies targeting the IL-6 pathway are in development for cancers, inflammatory and autoimmune diseases. Several anti-IL-6/IL-6 receptor monoclonal antibodies developed for targeted therapy have demonstrated promising results in both preclinical studies and clinical trials. Tocilizumab, an anti-IL-6 receptor antibody, is effective in the treatment of various autoimmune and inflammatory conditions notably rheumatoid arthritis. It is the only IL-6 pathway targeting agent approved by the regulatory agencies for clinical use. Siltuximab, an anti-IL-6 antibody, has been shown to have potential benefits treating various human cancers either as a single agent or in combination with other chemotherapy drugs. Several other anti-IL-6-based therapies are also under clinical development for various diseases. IL-6 antagonism has been shown to be a potential therapy for these disorders refractory to conventional drugs. New strategies, such as combination of IL-6 blockade with inhibition of other signaling pathways, may further improve IL-6-targeted immunotherapy of human diseases.
    Pharmacology [?] Therapeutics 09/2013; 141. DOI:10.1016/j.pharmthera.2013.09.004 · 7.75 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Almost 3 decades have passed since the discovery and cloning of IL-6, and a tremendous amount of work has contributed to the current knowledge of the biological functions of this cytokine, its receptor, and the signaling pathways that are activated. The understanding of the role of IL-6 in human disease has led to the development of novel therapeutic strategies that block the biological functions of IL-6. In clinical studies, IL-6 and IL-6 receptor antibodies have proven efficacy in rheumatoid arthritis, systemic juvenile idiopathic arthritis, and Castleman's disease, conditions that are known to be driven by IL-6. The focus of this overview is the role of IL-6 in the pathophysiology of hematological malignancies.
    Transfusion Medicine and Hemotherapy 10/2013; 40(5):336-343. DOI:10.1159/000354194 · 2.01 Impact Factor
Show more